Evidence map›Paper›PMID 39808439›Full record

ArticleDiabetes2025

Cisplatin Exposure Dysregulates Insulin Secretion in Male and Female Mice.

Lahari Basu, Lili Grieco-St-Pierre, Ma Enrica Angela Ching, John D H Stead, Antonio A Hanson, Jana Palaniyandi, Erin van Zyl, Myriam P Hoyeck, Kelsea S McKay, Kyle A van Allen and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lahari BasuDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Lili Grieco-St-PierreDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Ma Enrica Angela ChingDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
John D H SteadDepartment of Neuroscience, Carleton University, Ottawa, Ontario, Canada.
Antonio A HansonDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Jana PalaniyandiDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Erin van ZylDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Myriam P HoyeckDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Kelsea S McKayDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Kyle A van AllenDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.
Hyojin LeeDepartment of Biology, University of Ottawa, Ottawa, Ontario, Canada.
Xiao-Qing DaiAlberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
Austin BautistaAlberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
Evgenia FadzeyevaUniversity of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Erin E MulvihillUniversity of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Carole L YaukDepartment of Biology, University of Ottawa, Ottawa, Ontario, Canada.
Jan A MennigenDepartment of Biology, University of Ottawa, Ottawa, Ontario, Canada.
Patrick E MacDonaldAlberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada.
Jennifer E BruinDepartment of Biology and Institute of Biochemistry, Carleton University, Ottawa, Ontario, Canada.ORCID 0000-0003-2326-7819

Funding

Canadian Foundation for Innovation 233109Canadian Institutes of Health Research/Breakthrough T1D/Diabetes Canada 5-SRA-2021-1149-S-B/TG 179092CIHR 148451Diabetes Canada OG-3-21-5591-EMNatural Sciences and Engineering Research Council of Canada RGPIN-2024-04456
6 · The paper itself

Abstract

article highlightsCancer survivors who receive cisplatin chemotherapy have an increased risk of type 2 diabetes, but the underlying mechanisms remain unclear. The aim of this study was to investigate whether cisplatin impacts β-cell health and function, thereby contributing to increased type 2 diabetes risk in cancer survivors. In vivo and in vitro cisplatin exposure dysregulated insulin secretion in male and female mice. In vitro cisplatin exposure reduced oxygen consumption, impaired β-cell exocytotic capacity, and altered expression of genes within the insulin secretion pathway in mouse islets. Understanding how chemotherapeutic drugs cause β-cell injury is critical for designing targeted interventions to reduce the risk of cancer survivors developing type 2 diabetes after treatment.

Indexed as

Antineoplastic AgentsCisplatinInsulinInsulin-Secreting CellsInsulin SecretionAnimalsDiabetes Mellitus, Type 2FemaleMaleMiceMice, Inbred C57BLOxygen ConsumptionAntineoplastic AgentsCisplatinInsulin

Identifiers

PMID39808439
PMCPMC11926276

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.